anti-survivin mRNA-dendritic cell vaccine (Tricision Biotherapeutics (zhuhai))

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-survivin mRNA-dendritic cell vaccine (Tricision Biotherapeutics (zhuhai))

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapyCell and gene therapy > Gene therapy > mRNAVaccines > Development/production technology > Dendritic cell vaccine +[6]

Mechanisms of ActionBaculoviral IAP repeat-containing protein 5 modulators

TargetsBaculoviral IAP repeat-containing protein 5

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsYes

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBeijing Tricision Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tricision Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A